We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




ELISA IVD Test Noninvasively Diagnoses Bladder Cancer with Unprecedented Accuracy

By LabMedica International staff writers
Posted on 19 Dec 2023

Bladder cancer ranks as the tenth most prevalent cancer globally and is the sixth most common in men, with incidence rates of 9.6 per 100,000 and a mortality rate of 3.2 per 100,000 in the male population. Typically, patients with bladder cancer initially experience painless macroscopic hematuria - blood in the urine. Those presenting with hematuria often face the challenging decision of undergoing a cystoscopy, the gold standard in bladder cancer diagnosis, to confirm the presence of the disease and assess its extent if a lesion is suspected. Treatment options for bladder cancer vary depending on the risk category and the extent of muscle invasion. Regular follow-ups for non-muscle invasive bladder cancer usually involve urinary cytology and cystoscopy at intervals of three to six months for the first two years, then every six months up to five years, and annually thereafter.

BioCheetah Pte. Ltd. (Singapore) is revolutionizing the approach to bladder cancer diagnosis and patient follow-up by introducing innovative biomarkers for more efficient, non-invasive diagnostic and monitoring procedures. This new approach aims to overcome the limitations in early detection and ongoing surveillance of bladder cancer. BioCheetah's leading product, the VECanDx ELISA Test, is designed for non-invasive bladder cancer detection in patients with hematuria and those with recurrent bladder cancer.

BioCheetah’s ELISA IVD test utilizes the enzyme-linked immunosorbent assay (ELISA), which is routinely used in hospitals for identifying and quantifying disease-specific biomarkers from patient samples. The VECanDx ELISA Test leverages this standard procedure for the sensitive detection of five patented bladder cancer biomarkers. By employing immunoassays that target five unique protein biomarkers exclusive to bladder cancer, BioCheetah's multiplex biomarker panel offers exceptional accuracy in diagnosing bladder cancer, presenting a new, non-invasive option for detecting the disease in patients.

Related Links:
BioCheetah Pte Ltd.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.